← Leaderboards
Wen Wee Ma
State University Of New York At Buffalo
$737,204
Attributed
$2,552,817
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $452.2K · FY2012–19$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,552,817 · 2
By mechanism
R01$2,156,820 · 1
R21$395,997 · 1
Top collaborators
- Robert M Straubinger7 shared
- Chris Scott5 shared
- Niall Barron3 shared
- Martin Clynes2 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Robert M Straubinger$4,875,752
- Jonathan F Lovell$9,226,863
- Chris Scott$539,205
- Chong Cheng$2,440,190
- Niall Barron$327,737
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasNeoplasm MetastasisDrug FormulationsInhibitor/AntagonistMediatingNanoparticulateDrug CarriersDrug Delivery SystemsGenetic HeterogeneityIncidenceDepositionMalignant NeoplasmsBlood FlowNanoparticleDiagnosisCombined Modality TherapyBlood VesselsCharacteristicsBaseFda ApprovedCancer BiologyClinical TrialsCancer CellNeoplastic Cell
Grant awards (7)
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$416,494
R01 · FY2019 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2018 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2017 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2016 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$452,195
R01 · FY2015 · CA
Pancreas cancer combination therapy based on stromal modulators and nano-carriers$167,489
R21 · FY2013 · CA
Pancreas cancer combination therapy based on stromal modulators and nano-carriers$228,508
R21 · FY2012 · CA